|Target||Notch 2, Notch 3|
|Chemical and physical data|
|Molar mass||143.2 kDa g·mol−1|
Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In Jan 2015 the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer. Two early stage clinical trials have reported encouraging results.
- Notch signaling pathway, e.g. in embryo tissue development
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|